Antitumor activity of a ROR1 × CD3 bispecific antibody in non-small cell lung cancer

•R11 × v9 biAb specifically binds T cells and tumor cells simultaneously, and dose dependent cytotoxicity was detected in both ROR1 + NSCLC cell lines and two xenogeneic ROR1 + NSCLC transplantation mice models.•R11 × v9 biAb mediated T-cell derived proinflammatory cytokine secretion, boosted granzyme B and perforin production from CD8+ T cells, and recruited more CD4+ T cells and CD8+ T cells into the tumor tissues.•No harmful side effects were observed in two xenogeneic ROR1 + NSCLC transplantation mice models, warranting further preclinical and clinical studies of R11 × v9 biAb in NSCLC.